Pharmacology, biochemistry, and behavior
2001
Karen K. Szumlinski, R E Haskew, M Y Balogun et al.
28 citations
This study investigated the effects of pretreatment with the putative antiaddictive compound, ibogaine (IBO), and its synthetic derivative, 18-methoxycoronaridine (18-MC), on the changes in behaviour in an elevated plus maze and the changes in corticosterone (CORT) produced by a low dose of methamphetamine (METH). In the elevated plus maze, the acute administration of METH (0.1 mg/kg ip, -20...
Toxicon : official journal of the International Society on Toxinology
2001
Karen K. Szumlinski, Isabelle M Maisonneuve, Stanley D Glick
9 citations
Currently, no effective therapy has been approved for the treatment of addiction to stimulant drugs (e.g., cocaine, amphetamine and its methylated derivatives). However, preclinical studies indicate that the naturally-occurring indole alkaloid, ibogaine, and a synthetic iboga alkaloid congener, 18-methoxycoronaridine (18-MC), attenuate stimulant self-administration in laboratory animals. The in...
Annals of the New York Academy of Sciences
September 1, 2000
Stanley D Glick, Isabelle M Maisonneuve, Karen K. Szumlinski
89 citations
18-MC, a novel iboga alkaloid congener, is being developed as a potential treatment for multiple forms of drug abuse. Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; unlike ibogaine, 18-MC does not affect responding for a nondrug reinforcer (water). Both ibogaine...
Psychopharmacology
August 1, 2000
Karen K. Szumlinski, M Y Balogun, Isabelle M Maisonneuve et al.
28 citations
The phenomenon of sensitization has been theoretically implicated in mediating various aspects of drug addiction. Recent dose-response studies demonstrated that pretreatment with the putative antiaddictive agent, ibogaine (IBO), and a synthetic iboga alkaloid congener, 18-methoxycoronaridine (18-MC), increase the potency of cocaine to elicit behavioral sensitization, an effect proposed to...
European Journal of Pharmacology
June 16, 2000
Karen K. Szumlinski, Isabelle M Maisonneuve, Stanley D Glick
19 citations
To investigate a possible basis for the proposed anti-addictive property of ibogaine, the effects of ibogaine (40 mg/kg, i.p., 19 h earlier) on the expression of sensitization induced by cocaine were investigated. Ibogaine pretreatment potentiated the increase in the stereotypic effects of a cocaine challenge (20 mg/kg) in both sensitized (5 x 15 mg/kg, i.p.) and acutely treated rats. However,...
Psychopharmacology
July 1, 1999
Karen K. Szumlinski, Isabelle M Maisonneuve, Stanley D Glick
14 citations
Results of single-dose studies suggest that the effects of pretreatment with the putative anti-addictive compound, ibogaine, on drug-induced locomotor behavior depends on the previous drug history of the animal. To compare the effects of ibogaine pretreatment on the dose-locomotor response function for cocaine in rats treated chronically with either saline or cocaine. Rats were chronically...
Pharmacology, biochemistry, and behavior
July 1, 1999
Karen K. Szumlinski, Isabelle M Maisonneuve, Stanley D Glick
14 citations
Pretreatment (19 h) with the putative antiaddictive agent, ibogaine, has been shown previously to potentiate cocaine-induced locomotion in rats. The present study demonstrates that the magnitude of this effect of ibogaine is dependent on the previous cocaine history of the animal, on the time following ibogaine treatment, and on the number of ibogaine treatments. Compared to rats with no...
Behavioural Brain Research
December 1, 1997
J R Blackburn, Karen K. Szumlinski
22 citations
The neural basis of ibogaine's effects on drug-related behaviours is unclear. One possibility is that ibogaine interferes with the shared capacity of many addictive agents to stimulate brain dopamine activity, but reports of ibogaine effects on dopamine activity have been inconsistent. Our study suggests such inconsistencies may result from variations in prior drug exposure. If ibogaine blocks...